gw pharmaceuticals

warning: Creating default object from empty value in /home/hemporg/public_html/news/modules/taxonomy/taxonomy.pages.inc on line 34.

Study: Cannabis Component Reduces Seizures For Some Epilepsy Patients, According To Research

NYU Langone Center

By Michael Bachara
Hemp News

An oil derived from the cannabis plant sharply reduces violent seizures in young people according to a study published last Wednesday in the New England Journal of Medicine. The study focused on patients with Dravet syndrome, a severe type of epilepsy.

"This is the first solid, rigorously obtained scientific data that a marijuana compound is safe and effective for this problem," said Dr. Orrin Devinsky, a neurologist at New York University Langone Medical Center and primary author of the study.

U.S.: GW Pharma Moves To Monopolize CBD Market

CBD.jpg

By Derrick Stanley
Hemp News

Bruce Barcott of Leafly has exposed some actions taken by GW Pharma (NASDAQ: GWPH) that seem to attempt to limit competition from suppliers of CBD.

Lobbyists have been engaged in several states by the company and its U.S. subsidiary, Greenwich BioSciences, companies which are both supporting legislation in South Dakota and Nebraska that would “effectively give GW/Greenwich a temporary monopoly on legal CBD products” in those states for its Epidiolex.

If given FDA approval, Epidiolex could be on the market in early 2018. Legislation advancing in both South Dakota and Nebraska suggests that CBD would be permitted only from FDA-approved providers.

Barcott says GW Pharma and Greenwich BioSciences have hired lobbyists in Arizona, Florida, Idaho, Minnesota, Nebraska, South Dakota, Washington and Wisconsin and possibly in California. Barcott attempted to contact GW Pharma for comment but has not yet received a reply. Should GW Pharma succeed in stifling competition, it could have a serious impact on hopeful in-state poducers of CBD, as well as companies both foreign and domestic who extract CBD from industrial hemp.

Great Britain: Marijuana Extract Proven To Treat Rare Forms Of Epilepsy

A form of marijuana extract has again proven to be an effective treatment for several different types of epilepsy.

By Derrick Stanley
Hemp News

A pharmaceutical-grade form of marijuana extract has again proven to be an effective treatment for several different types of epilepsy.

The British company GW Pharmaceuticals has released successful results from the latest clinical trial of Epidiolex, a form of CBD-rich medication, Forbes reported.

It was the second trial for a rare type of epilepsy called Lennox Gastaut Dyndrome. Epidiolex was given to 86 patients who suffer from the disorder, while 85 patients received a placebo medication. Patients given the Epidiolex saw their seizures reduce by 44%, compared to a 22% reduction for those in placebo.

“Between the plant itself and the processing steps which are being taken, the product ends up being pure CBD,” said GW’s chief executive Justin Gower to Forbes.

GW Pharmaceuticals plans to file for FDA approval in the first half of 2017, although many similar CBD-based formulations are already available in states with legal medical marijuana laws, such as California and Colorado.

Global: Marijuana-Based Drug Found To Reduce Epileptic Seizures

Epidiolex[GWPharmaceuticals].jpg

By Steve Elliott
Hemp News

The first major clinical trial of an experimental drug derived from marijuana has shown that Epidiolex reduces epileptic seizures, the product's developer announced on Monday.

The shares of Big Pharma giant GW Pharmaceuticals more than doubled on Monday after the announcement.

GW said Epidiolex achieved the main goal of the trial, reducing convulsive seizures when compared with a placebo in patients with Dravet syndrome, a rare, severe form of epilepsy, reports Andrew Pollack at The New York Times.

If Epidiolex wins regulatory approval, as expected, it would be the first prescription drug that is extracted from marijuana. Marinol (Dronabinol), the THC capsules prescribed for nausea and appetite, use synthetic rather than plant-derived THC.

Epidiolex is a liquid containing cannabidiol (CBD), a non-psychoactive component of cannabis.

As many as one-third of the nearly 500,000 American children with epilepsy aren't sufficiently helped by existing Big Pharma drugs, according to GW. Parents of these children have, in desperation, tried medicinal cannabis extracts prepared by medical marijuana dispensaries.

U.S.: Former GW Pharmaceuticals Advisor Discusses Future of Medical Cannabis

DrEthanRusso[Ganjapreneur]

Cannabis business website Ganjapreneur has announced its latest podcast episode, which features prominent medical marijuana researcher Dr. Ethan Russo in a conversation about his research regarding the Endocannabinoid System — a unique system found in all vertebrates, including humans, which promotes homeostasis and a biological balance across bodily functions.

In the interview, Ganjapreneur podcast host Shango Los asks Dr. Russo about Endocannabinoid Deficiency (ECD) and the potential for it to be treated with cannabis. As Russo explains, ECD is just coming into general awareness now as a cause behind several conditions including Migraines, Fibromyalgia, Irritable Bowel Syndrome, Phantom Limb Pain, Infantile colic, Glaucoma, PTSD, Bipolar disease and others.

When used as a form of treatment, "A lot of what THC does is paralleled by the effects of... natural chemicals in the body that everyone has," Dr. Russo explained.

Before going public with his research, Dr. Russo worked for years as senior medical advisor for GW Pharmaceuticals; there, he oversaw three separate clinical trials for Sativex, one of the world's first cannabinoid-based medicines to be approved for public use.

Today, he is medical director at Phytecs, a company specializing in the production of cannabis-based treatments related to the endocannabinoid system. Due to legal complications and concerns over the federal legality of his work, Dr. Russo only began to speak publicly about his research earlier this year.

Syndicate content